References
- Sugiyama T, Hasegawa K, Kobayashi Y, et al. Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001–2011. J Am Heart Assoc. [Internet]. 2015 [cited 2018 Jan 31];4:e001445. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25801759
- Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. [Internet]. 2014 [cited 2018 Jan 31];35:1957–1970. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24419804
- Pedersen F, Butrymovich V, Kelbæk H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. [Internet]. 2014 [cited 2018 Jan 31];64:2101–2108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25457398
- Fokkema ML, James SK, Albertsson P, et al. Population trends in percutaneous coronary intervention. J Am Coll Cardiol. [Internet]. 2013 [cited 2018 Jan 31];61:1222–1230. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23500325
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. [Internet]. 2017 [cited 2018 Jan 31];39:119–177. Available from: http://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehx393/4095042/2017-ESC-Guidelines-for-the-management-of-acute
- Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. [Internet]. 2001 [cited 2018 Jan 31];344:1895–1903. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM200106213442503
- Fernandez-Rodriguez D, Regueiro A, Brugaletta S, et al. Optimization in stent implantation by manual thrombus aspiration in ST-segment-elevation myocardial infarction: findings from the EXAMINATION trial. Circ Cardiovasc Interv. [Internet]. 2014 [cited 2018 Feb 2];7:294–300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24867891
- Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size. J Am Coll Cardiol. [Internet]. 2009 [cited 2018 Jan 31];53:309–315. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19161878
- Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet. [Internet]. 2008 [cited 2018 Jan 31];371:1915–1920. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18539223
- Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST- elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. [Internet]. 2009 [cited 2018 Jan 31];30:2193–2203. Available from: https://academic.oup.com/eurheartj/article-abstract/30/18/2193/478660
- Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. [Internet]. 2015 [cited 2018 Jan 31];372:1389–1398. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25853743
- Fröbert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. [Internet]. 2013 [cited 2018 Jan 31];369:1587–1597. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1308789
- Jolly SS, Cairns JA, Yusuf S, et al. Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. Eur Heart J. [Internet]. 2015 [cited 2018 Jan 31];36:2364–2372. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26129947
- Jolly SS, James S, Džavík V, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. [Internet]. 2017 [cited 2018 Jan 31];135:143–152. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27941066
- Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. J Am Coll Cardiol. [Internet]. 2010 [cited 2018 Jan 31];56:1298–1306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20691553
- De Carlo M, Aquaro GD, Palmieri C, et al. A prospective randomized trial of thrombectomy versus no thrombectomy in patients with ST-segment elevation myocardial infarction and thrombus-rich lesions. JACC Cardiovasc Interv. [Internet]. 2012 [cited 2018 Jan 31];5:1223–1230. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23257370
- Kumbhani DJ, Bavry AA, Desai MY, et al. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty. J Am Coll Cardiol. [Internet]. 2013 [cited 2018 Jan 31];62:1409–1418. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23665372
- Loubeyre C, Morice M-C A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. 2002 [cited 2018 Feb 1]. Available from: https://pdfs.semanticscholar.org/150d/5adf009d8ad108a5e9ee164ada1a11fa21ec.pdf.
- Möckel M, Vollert J, Lansky AJ, et al. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol. [Internet]. 2011 [cited 2018 Feb 1];108:1697–1703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21906709
- Dudek D, Siudak Z, Janzon M, et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER registry. Am Heart J. [Internet]. 2008 [cited 2018 Feb 1];156:1147–1154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19033011
- Isaaz K, Robin C, Cerisier A, et al. A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coron Artery Dis. [Internet]. 2006 [cited 2018 Feb 1];17:261–269. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16728877
- Meneveau N, Séronde MF, Descotes-Genon V, et al. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients. Clin Res Cardiol. [Internet]. 2009 [cited 2018 Feb 1];98:257–264. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19205776
- Pascal J, Veugeois A, Slama M, et al. Delayed stenting for ST-elevation acute myocardial infarction in daily practice: a single-centre experience. Can J Cardiol. [Internet]. 2016 [cited 2018 Feb 1];32:988–995. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26838663
- Carrick D, Oldroyd KG, McEntegart M, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. [Internet]. 2014 [cited 2018 Feb 1];63:2088–2098. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0735109714011577
- Kelbæk H, Høfsten DE, Køber L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet (London, England). [Internet]. 2016 [cited 2018 Feb 1];387:2199–2206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27053444
- Belle L, Motreff P, Mangin L, et al. Comparison of immediate with delayed stenting using the minimalist immediate mechanical intervention approach in acute ST-segment–elevation myocardial infarction. Circ Cardiovasc Interv. [Internet]. 2016 [cited 2018 Feb 1];9:e003388. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26957418
- Kim JS, Lee HJ, Woong Yu C, et al. INNOVATION study (Impact of immediate stent implantation versus deferred stent implantation on infarct size and microvascular perfusion in patients with ST-Segment–elevation myocardial infarction). Circ Cardiovasc Interv. [Internet]. 2016 [cited 2018 Feb 1];9:e004101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27965296
- Qiao J, Pan L, Zhang B, et al. Deferred versus immediate stenting in patients with ST‐segment elevation myocardial infarction: a systematic review and meta‐analysis. J. Am. Heart Assoc. [Internet]. 2017 [cited 2018 Feb 1];6:e004838. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28275065.
- Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (Trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv. [Internet]. 2011 [cited 2018 Feb 1];4:14–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21251624
- Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute st-segment elevation myocardial infarction. JACC Cardiovasc Interv. [Internet]. 2011 [cited 2018 Feb 1];4:24–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21251625
- Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. [Internet]. 2010 [cited 2018 Feb 1];55:810–814. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20170821
- Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction. JAMA. [Internet]. 2005 [cited 2018 Feb 1];293:2109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15870414
- Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction the MULTISTRATEGY randomized trial. JAMA. [Internet]. 2008 [cited 2018 Feb 1];299:1788. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18375998
- Di Lorenzo E, De Luca G, Sauro R, et al. The PASEO (PaclitAxel or Sirolimus-Eluting stent versus bare metal stent in primary Angioplasty) randomized trial. JACC Cardiovasc Interv. [Internet]. 2009 [cited 2018 Feb 1];2:515–523. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19539255
- Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. [Internet]. 2009 [cited 2018 Feb 1];360:1946–1959. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19420364
- Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. [Internet]. 2007 [cited 2018 Feb 1];28:2706–2713. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehm402
- Holmvang L, Kelbæk H, Kaltoft A, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with st-segment elevation myocardial infarction. JACC Cardiovasc Interv. [Internet]. 2013 [cited 2018 Feb 1];6:548–553. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23683734
- Camenzind E, Steg PG, Wijns W. A cause for concern. Circulation. [Internet]. 2007 [cited 2018 Feb 1];115:1440–1455. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17344324
- Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans. J Am Coll Cardiol. [Internet]. 2006 [cited 2018 Feb 1];48:193–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16814667
- Räber L, Kelbæk H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction. JAMA. [Internet]. 2012 [cited 2018 Feb 1];308:777. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22910755
- Räber L, Kelbaek H, Taniwaki M, et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circ Cardiovasc Interv. [Internet]. 2014 [cited 2018 Feb 1];7:355–364. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24847017
- Sabate M, Cequier A, Iñiguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. [Internet]. 2012 [cited 2018 Feb 1];380:1482–1490. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22951305
- Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet (London, England). [Internet]. 2016 [cited 2018 Feb 1];387:357–366. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26520230
- Toušek P, Kočka V, Malý M, et al. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. EuroIntervention. [Internet]. 2016 [cited 2018 Feb 1];12:23–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27173858
- Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. [Internet]. 2014 [cited 2018 Feb 1];35:777–786. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24394380
- Cortese B, Ielasi A, Romagnoli E, et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol. [Internet]. 2015 [cited 2018 Feb 1];116:705–710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26100584
- Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial. Eur Heart J. [Internet]. 2016 [cited 2018 Feb 1];37:229–240. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26405232
- Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in st-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison. JACC Cardiovasc Interv. [Internet]. 2015 [cited 2018 Feb 1];8:189–197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25616924
- Brugaletta S, Gori T, Low AF, et al. ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison. Int J Cardiol. [Internet]. 2016 [cited 2018 Feb 1];214:483–484. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27096965
- Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. [Internet]. 2016 [cited 2018 Feb 1];388:2479–2491. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27806897
- Wykrzykowska JJ, Kraak RP, Hofma SH, et al. Bioresorbable Scaffolds versus Metallic Stents in routine PCI. N Engl J Med. [Internet]. 2017 [cited 2018 Feb 1];376:2319–2328. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1614954.
- Kereiakes DJ, Ellis SG, Metzger C, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds. J Am Coll Cardiol. [Internet]. 2017 [cited 2018 Feb 1];70:2852–2862. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29100702
- Ielasi A, Campo G, Rapetto C, et al. A prospective evaluation of a pre-specified absorb BVS implantation strategy in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. [Internet]. 2017 [cited 2018 Feb 1];10:1855–1864. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28935077
- Haude M, Ince H, Abizaid A, et al. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J. [Internet]. 2016 [cited 2018 Feb 1];37:2701–2709. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27190094
- Dziewierz A, Siudak Z, Rakowski T, et al. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with st-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Am J Cardiol. [Internet]. 2010 [cited 2018 Feb 1];106:342–347. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20643243
- Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. [Internet]. 2010 [cited 2018 Mar 8];96:662–667. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19778920
- Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. [Internet]. 2013 [cited 2018 Feb 1];369:1115–1123. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1305520
- Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing Primary percutaneous coronary intervention for STEMI and multivessel disease. J Am Coll Cardiol. [Internet]. 2015 [cited 2018 Feb 1];65:963–972. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25766941
- Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet (London, England). [Internet]. 2015 [cited 2018 Feb 1];386:665–671. Available from.http://www.ncbi.nlm.nih.gov/pubmed/26347918
- Smits PC, Abdel-Wahab M, F-J N, et al. Fractional flow reserve–guided multivessel angioplasty in myocardial infarction. N Engl J Med. [Internet]. 2017 [cited 2018 Feb 1];376:1234–1244. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28317428
- Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. [Internet]. 2017 [cited 2018 Feb 1];377:2419–2432. Available from.http://www.nejm.org/doi/10.1056/NEJMoa1710261
- Ibanez B, Halvorsen S, Roffi M, et al. Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. Eur Heart J. [Internet]. 2018 [cited 2018 Oct 12]; Available from: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy294/5020748
- Kolte D, Khera S, Aronow WS, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. [Internet]. 2014 [cited 2018 Feb 1];3:e000590–e000590. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24419737
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. [Internet]. 2016 [cited 2018 Feb 20];37:2129–2200. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw128
- Atkinson TM, Ohman EM, O’Neill WW, et al. A practical approach to mechanical circulatory support in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. [Internet]. 2016 [cited 2018 Mar 5];9:871–883. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27151604
- Waksman R, Weiss AT, Gotsman MS, et al. Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J. [Internet]. 1993 [cited 2018 Feb 1];14:71–74. Available from: https://watermark.silverchair.com/14-1-71.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAbMwggGvBgkqhkiG9w0BBwagggGgMIIBnAIBADCCAZUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMtprEgTJVEmw_goZ9AgEQgIIBZsmdrd2xLoFtfOsRP8ipUAOGxJH16TTcYhYKLFjT1QNuZcvt4eZm0dlF0MKukj52dgw1xG5_kzeXcZqP4i1_95L2n0gVD_MgAyiU4CReGT59Blu88LUszqUrancxpoXZnf2IkItCK1p8ELer2gUxHZhjvfkgXVsw0FFN2e1hdJi13PBMrVJ4U2xovrYQLxANCzeffBLTkBAz2OpCUaPwaR3k2aDo_ZokZ0NEjohEmbpakxP6DpFXMCgSvAZjoK156Ih4xK0NfMCdhztrPWiIelr3Kncpd8AsibjPIvsOxNJgChWrShiRiLozrPBJK8ttPmSjjllZPP6qcR0KUoZfHem0gWD4p0mrVd_86noe748eLCAyT7ZhhfuhT4TkDIrQV0ybXZpUEO8IaKGviZBFRo7fvkNYh_S-nE_7JCezjgxeb4yrlGk_xp3TF88WLKxQp-zwZjCyelMkrcdEnHL_nA_nPteCn_o
- Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. [Internet]. 1992 [cited 2018 Feb 1];20:1482–1489. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1452920
- Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. [Internet]. 2008 [cited 2018 Feb 1];30:459–468. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19168529
- Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock. JAMA. [Internet]. 2011 [cited 2018 Feb 1];306:1329. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21878431
- Ohman EM, Nanas J, Stomel RJ, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis. [Internet]. 2005 [cited 2018 Feb 1];19:33–39. Available from: http://link.springer.com/10.1007/s11239-005-0938-0
- Prondzinsky R, Lemm H, Swyter M, et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome*. Crit Care Med. [Internet]. 2010 [cited 2018 Feb 1];38:152–160. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19770739
- Thiele H, Zeymer U, Neumann F-J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. [Internet]. 2012 [cited 2018 Feb 1];367:1287–1296. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22920912
- Thiele H, Zeymer U, Neumann F-J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. [Internet]. 2013 [cited 2018 Feb 1];382:1638–1645. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24011548
- Ahmad Y, Sen S, Mj S-S, et al. Intra-aortic balloon pump therapy for acute myocardial infarction. JAMA Intern Med. [Internet]. 2015 [cited 2018 Feb 1];175:931. Available from.http://www.ncbi.nlm.nih.gov/pubmed/25822657
- Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the impella 2.5 device. J Am Coll Cardiol. [Internet]. 2009 [cited 2018 Feb 1];54:2430–2434. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20082934
- Maini B, Naidu SS, Mulukutla S, et al. Real-world use of the Impella 2.5 circulatory support system in complex high-risk percutaneous coronary intervention: the USpella registry. Catheter Cardiovasc Interv. [Internet]. 2012 [cited 2018 Feb 1];80:717–725. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22105829
- Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. [Internet]. 2008 [cited 2018 Feb 1];52:1584–1588. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19007597
- Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. [Internet]. 2017 [cited 2018 Feb 1];69:278–287. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27810347
- Thiele H, Lauer B, Hambrecht R, et al. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. [Internet]. 2001 [cited 2018 Feb 1];104:2917–2922. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11739306
- Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. [Internet]. 2006 [cited 2018 Feb 1];152:469.e1–469.e8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16923414
- Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J. [Internet]. 2017 [cited 2018 Oct 12];38:3523–3531. Available from: http://academic.oup.com/eurheartj/article/38/47/3523/3935095
- Biswajit Kar L, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. [Internet]. 2011 [cited 2018 Feb 1];57:688–696. Available from: http://content.onlinejacc.org/cgi/content/full/57/6/688
- Burkhoff D, Sayer G, Doshi D, et al. Hemodynamics of mechanical circulatory support. 2015 [cited 2018 Feb 1]. Available from: http://danielburkhoff.com/papers/pdf/DB-Reference-246.pdf
- Petroni T, Harrois A, Amour J, et al. Intra-aortic balloon pump effects on macrocirculation and microcirculation in cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation*. Crit Care Med. [Internet]. 2014 [cited 2018 Feb 1];42:2075–2082. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24810530
- Cheng A, Swartz MF, Massey HT. Impella to unload the left ventricle during peripheral extracorporeal membrane oxygenation. ASAIO J. [Internet]. 2013 [cited 2018 Feb 1];59:533–536. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23995997
- Abrams D, Agerstrand CL, Biscotti M, et al. Extracorporeal membrane oxygenation in the management of diffuse alveolar hemorrhage. ASAIO J. [Internet]. 2015 [cited 2018 Feb 1];61:216–218. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25485559
- Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. [Internet]. 2014 [cited 2018 Feb 1];97:610–616. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24210621
- Sheu -J-J, Tsai T-H, Lee F-Y, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. [ cited 2018 Feb 1]. Available from: http://ocean.sci-hub.tw/58c5676a60d6d8afe6f3c372519c3888/10.1097%40ccm.0b013e3181e8acf7.pdf
- Muller G, Flecher E, Lebreton G, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med. [Internet]. 2016 [cited 2018 Feb 1];42:370–378. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26825953
- Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. [Internet]. 2016 [cited 2018 Oct 13];42:1922–1934. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27647331